undamentalytics Newsletter
Sign in

Urogen Pharma Ltd. balance sheet

At the end of fiscal 2025, Urogen Pharma Ltd. had total assets of $200m, total liabilities of $306m and shareholders' equity of −$105m. It held $111m in cash against $125m of debt: net debt of $14.3m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2137101505344559517211179
Receivables0———7121315203389
Inventory00——254691625
Total current assets2274102149116114129169276186235
Total assets2376104202122120136178286200253
Accounts payable—3453667111215
Deferred revenue (current)—1—————————
Total current liabilities37131921222431464662
Long-term debt—————09899122122189
Total debt0000009899122125200
Total liabilities77132226111225244295306385
Shareholders' equity166990180968−89−65−9−105−132
Net debt (negative = net cash)−21−37−101−50−53−44424−5014121
Shares outstanding9m—16m21m22m22m23m32m42m48m49m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ABUS vs URGNURGN vs VALNNUVB vs URGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Urogen Pharma Ltd.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Urogen Pharma Ltd.